Amgen Inc. (NASDAQ:AMGN) Shares Bought by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC grew its stake in Amgen Inc. (NASDAQ:AMGN) by 4.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 18,899 shares of the medical research company’s stock after purchasing an additional 801 shares during the period. OneDigital Investment Advisors LLC’s holdings in Amgen were worth $6,090,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Intelligence Driven Advisers LLC grew its stake in shares of Amgen by 48.5% during the 3rd quarter. Intelligence Driven Advisers LLC now owns 964 shares of the medical research company’s stock worth $310,000 after purchasing an additional 315 shares during the period. Tokio Marine Asset Management Co. Ltd. grew its position in Amgen by 5.1% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 15,412 shares of the medical research company’s stock valued at $4,966,000 after buying an additional 749 shares during the period. Unionview LLC increased its holdings in Amgen by 3.8% in the third quarter. Unionview LLC now owns 876 shares of the medical research company’s stock valued at $282,000 after buying an additional 32 shares in the last quarter. Metis Global Partners LLC raised its position in shares of Amgen by 2.6% in the third quarter. Metis Global Partners LLC now owns 25,755 shares of the medical research company’s stock worth $8,299,000 after acquiring an additional 657 shares during the period. Finally, Planning Capital Management Corp boosted its stake in shares of Amgen by 8.7% during the 3rd quarter. Planning Capital Management Corp now owns 665 shares of the medical research company’s stock worth $214,000 after acquiring an additional 53 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ AMGN opened at $283.61 on Friday. The stock has a fifty day simple moving average of $321.59 and a 200-day simple moving average of $318.00. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The stock has a market cap of $152.45 billion, a PE ratio of 36.31, a P/E/G ratio of 2.69 and a beta of 0.60. Amgen Inc. has a twelve month low of $260.52 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. During the same period last year, the business earned $4.96 earnings per share. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. Equities analysts anticipate that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 3.17%. Amgen’s dividend payout ratio is currently 115.24%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on AMGN shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 price target on shares of Amgen in a report on Tuesday, October 22nd. Barclays lifted their price target on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Wolfe Research assumed coverage on shares of Amgen in a report on Friday. They set a “peer perform” rating on the stock. Truist Financial cut shares of Amgen from a “buy” rating to a “hold” rating and boosted their target price for the stock from $320.00 to $333.00 in a research note on Monday, October 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of Amgen in a research note on Tuesday. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and a consensus price target of $333.57.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.